
Opinion|Videos|December 5, 2025
Selectivity of TYK2 Inhibition in Psoriasis
Next-generation TIC-2 inhibitors show remarkable selectivity, enhancing efficacy while minimizing side effects, offering insights into immune system safety.
Advertisement
Episodes in this series

Panelists discuss the questions below in this video.
How does the selectivity of TYK2 inhibition differ from JAK inhibition?
At what level of pathway inhibition (% inhibition of IL-12, IL-23, IFN) do we see efficacy without safety liabilities, and how narrow or wide is this therapeutic window compared to JAK inhibitors?
Loss-of-function TYK2 variants have been linked to protection from psoriasis. How do these genetic findings inform our understanding of TYK2’s role and support selective inhibition as a therapeutic strategy?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
Machine Learning Model Predicts Type 2 Diabetes Risk Up To 10 Years Out
3
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
4
ACCESS: Aleniglipron Achieves Up To 11.3% Weight Loss in Phase 2b Obesity Trial
5



























































